Production of monoclonal antibody to quantify serum CA125 concentration in breast and ovarian cancer patients

Nguyen Thi Xuan; Nguyen Trong Ha

doi:10.15625/2615-9023/v42n4.15095

Author affiliations

Authors

Nguyen Thi Xuan Institute of Genome Research, Vietnam Academy of Science and Technology https://orcid.org/0000-0003-3494-5136
Nguyen Trong Ha

DOI:

https://doi.org/10.15625/2615-9023/v42n4.15095

Keywords:

CA-125, breast cancer, ELISA, ovarian cancer, monoclonal antibodies.

Abstract

Ovarian carcinoma (OC) and breast cancer (BC) are mainly caused by alterations in genes such as BRCA1 and BRCA2, which are involved in differentiation and survival of cancer cells. The protein CA125 (MUC16) is released by cancer cells in most OC and a few BC patients. The cut-off point of CA125 level for tumor growth and metastasis is 35 U/mL. Production of CA125 monoclonal antidody (mAb) to determine expression level of this antigen by ELISA has been well known. In this study, we aimed to generate CA125-specific mAb for developing a new in-house ELISA kit. To this end, BALB/c mice were immunized with CA125 protein and splenocytes of immunized mice were fused with myeloma Sp2/0 cells. Efficiency of mAbs secreted from the hybridoma clones was examined by ELISA and flow cytometry analysis. As a result, among 3 stable hybridoma cell lines identified, A1 clone attained about 90% positive for anti-CA125 mAb, whereas H1 and H3 clones were about 40% and 50% positive for anti-CA125 mAb, respectively. By flow cytometry analysis, anti-CA125 mAb from A1 clone was more specific to CA125 antigen present in OVCAR -3 cells than those from H1 or H3 clone. In addition, the isotype of the obtained mAb was specific IgG1 and Kappa light chain. In conclusion, the mouse anti-human CA125 mAb generated in our lab was specifically binding to CA125 antigen and used as the capture antibody in sandwich ELISA system for early diagnosis as well as monitoring therapeutic response in OC patients.

Downloads

Download data is not yet available.

Metrics

Metrics Loading ...

References

Bast R. C., Jr., Klug T. L., St John E., Jenison E., Niloff J. M., Lazarus H., Berkowitz R. S., Leavitt T., Griffiths C. T., Parker L., Zurawski V. R., Jr., Knapp R. C., 1983. A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer. N Engl J Med, 309: 883–887.

Birgen D., Ertem U., Duru F., Sahin G., Yuksek N., Bozkurt C., Karacan C. D., Aksoy C., 2005. Serum Ca 125 levels in children with acute leukemia and lymphoma. Leuk Lymphoma, 46: 1177–1181.

Bottoni P., Scatena R., 2015. The Role of CA 125 as Tumor Marker: Biochemical and Clinical Aspects. Adv Exp Med Biol, 867: 229–244.

Coward J. I., Middleton K., Murphy F., 2015. New perspectives on targeted therapy in ovarian cancer. Int J Womens Health, 7: 189–203.

Cramer D. W., Vitonis A. F., Welch W. R., Terry K. L., Goodman A., Rueda B. R., Berkowitz R. S., 2010. Correlates of the preoperative level of CA125 at presentation of ovarian cancer. Gynecol Oncol, 119: 462–468.

Felder M., Kapur A., Gonzalez-Bosquet J., Horibata S., Heintz J., Albrecht R., Fass L., Kaur J., Hu K., Shojaei H., Whelan R. J., Patankar M. S., 2014. MUC16 (CA125): tumor biomarker to cancer therapy, a work in progress. Mol Cancer, 13: 129.

Ford D., Easton D. F., Stratton M., Narod S., Goldgar D., Devilee P., Bishop D. T., Weber B., Lenoir G., Chang-Claude J., Sobol H., Teare M. D., Struewing J., Arason A., Scherneck S., Peto J., Rebbeck T. R., Tonin P., Neuhausen S., Barkardottir R., Eyfjord J., Lynch H., Ponder B. A., Gayther S. A., Zelada-Hedman M., 1998. Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium. Am J Hum Genet, 62: 676–689.

Gaetje R., Winnekendonk D. W., Ahr A., Kaufmann M., 2002. Ovarian cancer antigen CA 125 influences adhesion of human and mammalian cell lines in vitro. Clin Exp Obstet Gynecol, 29: 34–36.

Kohler G., Milstein C., 1975. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature, 256: 495–497.

Kohler G., Milstein C., 1992. Continuous cultures of fused cells secreting antibody of predefined specificity. 1975. Biotechnology, 24: 524–526.

Libson S., Lippman M., 2014. A review of clinical aspects of breast cancer. Int Rev Psychiatry, 26: 4–15.

McIntosh M. W., Drescher C., Karlan B., Scholler N., Urban N., Hellstrom K. E., Hellstrom I., 2004. Combining CA 125 and SMR serum markers for diagnosis and early detection of ovarian carcinoma. Gynecol Oncol, 95: 9–15.

O'Brien T. J., Beard J. B., Underwood L. J., Dennis R. A., Santin A. D., York L., 2001. The CA 125 gene: an extracellular superstructure dominated by repeat sequences. Tumour Biol, 22: 348–366.

Reinartz S., Failer S., Schuell T., Wagner U., 2012. CA125 (MUC16) gene silencing suppresses growth properties of ovarian and breast cancer cells. Eur J Cancer, 48: 1558–1569.

Senapati S., Das S., Batra S. K., 2010. Mucin-interacting proteins: from function to therapeutics. Trends Biochem Sci, 35: 236–245.

Vasen H. F., Tesfay E., Boonstra H., Mourits M. J., Rutgers E., Verheyen R., Oosterwijk J., Beex L., 2005. Early detection of breast and ovarian cancer in families with BRCA mutations. Eur J Cancer, 41: 549–554.

Yoo E. M., Chintalacharuvu K. R., Penichet M. L., Morrison S. L., 2002. Myeloma expression systems. J Immunol Methods, 261: 1–20.

Zhao S., Mei Y., Wang J., Zhang K., Ma R., 2016. Different Levels of CEA, CA153 and CA125 in Milk and Benign and Malignant Nipple Discharge. PLoS One, 11: e0157639.